<DOC>
	<DOC>NCT02546284</DOC>
	<brief_summary>This is a multicenter, open-label, repeat-dose, Phase 1 Dose Escalation Study to evaluate safety, pharmacokinetics, and clinical activity.</brief_summary>
	<brief_title>Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)</brief_title>
	<detailed_description>The purpose of the study is to examine the safety and determine the recommended Phase 2 dose of lenzilumab (KB003) when administered to subjects with previously treated CMML who meet the entry criteria. Study will begin enrollment in July 2016.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
	<mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
	<criteria>Confirmed diagnosis of CMML CMML that is refractory to, or progressed following treatment with a hypomethylating agent or other standard of care treatment Eastern Cooperative Oncology Group (ECOG) score â‰¤ 2 Able to provide bone marrow biopsy samples Acceptable laboratory results Leukemia other than CMML Recent chemotherapy or radiation therapy (within 14 days before first dose of lenzilumab) Concurrent use of human granulocytemacrophage colonystimulating factor Pregnant or breastfeeding Know HIV virus infection History of another malignancy within the past 2 years (some skin cancer and prostate cancers permitted) Significant intercurrent illness History or current diagnosis of Pulmonary Alveolar Proteinosis or Hypoxemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CMML</keyword>
</DOC>